The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 5, 1997, Pages 563-573

  Yan, Jieming ^b   Tyring, Stephen K ^b   McCrary, Monica M ^b   Lee, Patricia C ^b   Haworth, Stephen ^b   Raymond, Ralph ^b   Olsen, Steven J ^b   Diasio, Robert B ^a  

^a University of Alabama at Birmingham   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLITE; SORIVUDINE; STEROID; URACIL DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; ENZYME ACTIVITY; FEMALE; HERPES ZOSTER; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TABLET;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BROMOURACIL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; HERPES ZOSTER; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OXIDOREDUCTASES; SOFTWARE; URACIL;

EID: 0030951083     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90136-3     Document Type: Article

References (25)

1. Machida H, Nishitani M. Drug susceptibilities of isolates of varicella-zoster virus in a clinical study of oral brovavir. Microbiol Immunol 1990;34:407-11.
2. Suzatani T, Machida H, Sakuma T, Azuma M. Effects of various nucleosides on antiviral activity and metabolism of 1-beta-D-arabinofuranosoyl-E-5 (2-bromovinyl) uracil against herpes virus types 1 and 2. Antimicrob Agents Chemother 1988;32:1547-51.
3. Lin JC, Machida H. Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofurasnosyl-E-5 (2-bromovinyl) uracil and E-5 (2-bromovinyl)-2-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication. Antimcicrob Agents Chemother 1988;32:1068-107.
4. Whitley RJ. Sorivudine: a promising drug for the treatment of varicella-zoster virus infection. Neurology 1995;45:S73-5.
5. Nakamura H, Omori S, Kitada K, Mochida A. Prevention of drug interactions and its countermeasure [Japanese]. J Toxicol Sci 1994;19:89-93.
6. Desgranges C, Razaka G, DeClerq E. Effect of E-5-(2-bromovinyl)-uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 1986;46:1094-101.
7. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-37.
8. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987;47:2203-6.
9. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988;81: 47-51.
10. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML, Mirkin BL. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985;313:245-9.
11. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer 1991;68: 499-501.
12. Lyss AP, Lilenbaum RC, Harris BE, Diasio RB. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 1993;53:5433-8.
13. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver: population characteristics, newly identified deficiency patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53: 5433-8.
14. Houyan P, Gay C, Chatelut E, Canal P, Milano G. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst 1993;85:1602-3.
15. Iigo M, Araki E, Nakajima Y, Hoshi A, DeClerq E. Enhancing effect of bromovinyluracil on antitumour activity of 5-fluorouracil against adenocarcinoma 755 in mice: increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. Biochem Pharmacol 1988;37:1609-13.
16. Ben-Efraim S, Shoval S, DeClerq E. Enhancing effect of bromovinyluracil on antitumour activity of 5-fluorouracil in mice bearing MOPC-315 plasmacytomas. Br J Cancer 1986;54:847-51.
17. Chazal M, Etienne MC, Renee N, Bourgeon A, Richelme H, Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 1996;2:507-10.
18. Harris BE, Song S, Soong S, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
19. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
20. Sommadossi JP, Gewirtz DA, Diasio RB, Aubert C, Cano JP, Goldman ID. Rapid catabolism of 5-fluorouracil in freshly isolated hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem 1982;257:8171-6.
21. Fleming RA, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne P, et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 1993; 29A:740-4.
22. De Abreu RA, Bakkeren JA, Braakhekke J, Gabreels FJ, Mass JM Sengers RC. Dihydropyrimidine dehydrogenase deficiency in a family, leading to elevated levels of uracil and thymine. Adv Exp Med Biol 1986; 195A:71-6.
23. Khor SP, Lucas S, Schilsky R, Burris H, Von Hoff DD, Zhang R, et al. A phase I pharmacokinetics study of 5-ethynyluracil plus 5-fluorouracil in cancer patients with solid tumors [abstract]. Proc Am Assoc Cancer Res 1995;36:1439.
24. Peck R, Wiggs R, Callaghan J, Wootton R, Crome P, Fraser I, et al. Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine. Clin Pharmacol Ther 1996;59:22-31.
25. Spector T, Harrington JA, Porter DJT. 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 1993;12:2243-8.